


Accelerating the Development of Life Transforming Medicines which have the Potential to Generate Significant Value




- ★ Orphan drug designations in at least one indication
- US Breakthrough and/or EU PRIME designations in at least one indication
- Japan SAKIGAKE and/or China Breakthrough designations in at least one indication

Late-stage program: Program in or expected to be in potential pivotal trial or having achieved proof-of-concept.

- Approved
- Target Filing, anticipated year of filing for regulatory approval
- Targeted pivotal study / Phase 3 start
- Proof-of-concept/Dose ranging Phase 2 study
- Milestone achieved

All timelines are approximate estimates as of July 30th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Maximizing Potential of Marketed Portfolio Through LCM Expansions



Approved

Target Filing

Phase 3 study start

Proof-of-concept study readout

Milestone achieved

All timelines are approximate estimates as of July 30th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Glossary of Abbreviations



Regional Abbreviations:

CN: China; EU: Europe; JP: Japan; U.S.: United States of America

AA	anemia-associated
AATD	α 1-antitrypsin deficiency
AATD LD	α 1-antitrypsin deficiency associated liver disease
ADAMTS13	a disintegrin-like and metalloproteinase with a thrombospondin type 1 motifs 13
ADC	antibody–drug conjugate
ASCO	American Society of Clinical Oncology
ASH	American Society of Hematology
ASN	American Society of Nephrology
AVA	Advanced Vial Access
BID	bis in die, twice a day
BDT	breakthrough therapy designation
CAR NK	chimeric antigen receptor natural killer cell
CHMP	Committee for Medicinal Products for Human Use
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy
CML	chronic myeloid leukemia
CMV	cytomegalovirus
CP-CML	chronic-phase chronic myeloid leukemia
cTTP	congenital thrombotic thrombocytopenic purpura
DOAC	direct oral anti-coagulation
EDS	excessive daytime sleepiness
EMA	European Medicines Agency
ERC	Enhanced Removal Capabilities
ESS	Epworth Sleepiness Scale
FDA	U.S. Food & Drug Administration
FINI	Functional Impacts of Narcolepsy Instrument
FL	front line
fSCIG	facilitated Subcutaneous Immunoglobulin
FY	fiscal year
GI	gastrointestinal

H2H	head-to-head
HAE	hereditary angioedema
HemA	hemophilia A
HL	Hodgkin lymphoma
HS	hidradenitis suppurativa
IBD	inflammatory bowel disease
IgA	immunoglobulin A
IgAN	immunoglobulin A nephropathy
IgG	immunoglobulin G
IH	idiopathic hypersomnia
IND	investigational new drug
INN	international non-proprietary name
ISTH	International Society on Thrombosis and Haemostasis
ITP	immune thrombocytopenia
iTTP	immune thrombotic thrombocytopenic purpura
IV	intravenous
JAK	Janus kinase
LCM	lifecycle management
LTE	long-term extension
MDS	myelodysplastic syndrome
MF	myelofibrosis
MMN	multifocal motor neuropathy
MSA	multiple system atrophy
MWT	maintenance of wakefulness test
NDA	new drug application
NK	natural killer
NME	new molecular entity
NMPA	(China's) National Medical Products Administration
NSS-CT	Narcolepsy Severity Scale

NT1 or 2	narcolepsy type 1 or 2
OX2R	orexin 2 receptor
PDT	plasma derived therapies
PGI-C	Patient Clinical Global Impression of Change
PID	primary immunodeficiency
PK	pharmacokinetics
PMDA	Japan's Pharmaceuticals and Medical Devices Agency
POC	proof of concept
PRIME	Priority medicines scheme by EMA
PROC	platinum-resistant ovarian cancer
PsO	psoriasis
PSOC	platinum-sensitive ovarian cancer
PTRS	probability of technical and regulatory success
PV	polycythemia vera
PVT	Psychomotor Vigilance Task
QD	quaque die, every day
QOL	quality of life
SC	subcutaneous formulation
SF-36	Short Form-36 Survey
SID	secondary immunodeficiency
SOC	standard of care
TKI	tyrosine kinase inhibitor
TYK2	tyrosine kinase 2
UC	ulcerative colitis
vWD	von Willebrand disease
WCR	weekly cataplexy rate
wk(s)	week(s)
WW	worldwide